Header Logo

Connection

SUSAN BLANEY to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications SUSAN BLANEY has written about Antineoplastic Agents.
SUSAN BLANEY
Connection Strength
6.745
Antineoplastic Agents
  1. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer. 2018 08; 65(8):e27066.
    View in: PubMed
    Score: 0.317
  2. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 Oct; 62(10):1717-24.
    View in: PubMed
    Score: 0.258
  3. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Sep; 62(9):1562-6.
    View in: PubMed
    Score: 0.257
  4. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2015 Feb; 17(2):303-11.
    View in: PubMed
    Score: 0.250
  5. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112). Clin Cancer Res. 2013 Dec 01; 19(23):6578-84.
    View in: PubMed
    Score: 0.231
  6. A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study. Pediatr Blood Cancer. 2013 Apr; 60(4):627-32.
    View in: PubMed
    Score: 0.215
  7. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012 Nov 01; 18(21):6011-22.
    View in: PubMed
    Score: 0.214
  8. Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). J Neurooncol. 2012 Sep; 109(3):565-71.
    View in: PubMed
    Score: 0.212
  9. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol. 2012 Apr; 69(4):1021-7.
    View in: PubMed
    Score: 0.204
  10. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011 Aug 01; 17(15):5113-22.
    View in: PubMed
    Score: 0.197
  11. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol. 2011 Jan 20; 29(3):316-23.
    View in: PubMed
    Score: 0.190
  12. Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2010 Jul 15; 55(1):119-22.
    View in: PubMed
    Score: 0.185
  13. Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates. Cancer Chemother Pharmacol. 2011 Apr; 67(4):809-12.
    View in: PubMed
    Score: 0.184
  14. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. Cancer Chemother Pharmacol. 2008 Apr; 61(4):647-52.
    View in: PubMed
    Score: 0.149
  15. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 01; 13(5):1516-22.
    View in: PubMed
    Score: 0.146
  16. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. Cancer Chemother Pharmacol. 2007 May; 59(6):743-7.
    View in: PubMed
    Score: 0.141
  17. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol. 2006 Aug 01; 24(22):3678-85.
    View in: PubMed
    Score: 0.140
  18. New agents for intrathecal administration. Cancer Invest. 2006 Aug-Sep; 24(5):528-34.
    View in: PubMed
    Score: 0.140
  19. New approaches to drug development in pediatric oncology. Cancer J. 2005 Jul-Aug; 11(4):324-30.
    View in: PubMed
    Score: 0.130
  20. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005 Mar 01; 23(7):1555-63.
    View in: PubMed
    Score: 0.127
  21. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol. 2005 Jan 20; 23(3):525-31.
    View in: PubMed
    Score: 0.126
  22. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res. 2004 Apr 01; 10(7):2525-9.
    View in: PubMed
    Score: 0.119
  23. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jun; 53(6):527-32.
    View in: PubMed
    Score: 0.119
  24. Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. Cancer Chemother Pharmacol. 2003 Nov; 52(5):417-23.
    View in: PubMed
    Score: 0.114
  25. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003 Jan 01; 21(1):143-7.
    View in: PubMed
    Score: 0.110
  26. Intrathecal chemotherapy. Crit Rev Oncol Hematol. 2001 Mar; 37(3):227-36.
    View in: PubMed
    Score: 0.096
  27. The development of camptothecin analogs in childhood cancers. Oncologist. 2001; 6(6):506-16.
    View in: PubMed
    Score: 0.095
  28. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clin Cancer Res. 2019 06 01; 25(11):3229-3238.
    View in: PubMed
    Score: 0.084
  29. New cytotoxic drugs for intrathecal administration. J Neurooncol. 1998 Jun-Jul; 38(2-3):219-23.
    View in: PubMed
    Score: 0.080
  30. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 08; 65(8):e27077.
    View in: PubMed
    Score: 0.079
  31. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
    View in: PubMed
    Score: 0.078
  32. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
    View in: PubMed
    Score: 0.070
  33. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. Cancer Med. 2016 07; 5(7):1416-24.
    View in: PubMed
    Score: 0.069
  34. Pharmacologic strategies for the treatment of meningeal malignancy. Invest New Drugs. 1996; 14(1):69-85.
    View in: PubMed
    Score: 0.067
  35. Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol. 1995; 36(2):121-4.
    View in: PubMed
    Score: 0.063
  36. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014 Sep; 61(9):1598-602.
    View in: PubMed
    Score: 0.060
  37. A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2013 Sep; 114(2):173-9.
    View in: PubMed
    Score: 0.057
  38. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013 May; 14(6):472-80.
    View in: PubMed
    Score: 0.056
  39. Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts. Biochem Pharmacol. 1993 Apr 06; 45(7):1493-501.
    View in: PubMed
    Score: 0.056
  40. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 1993 Mar 01; 53(5):1032-6.
    View in: PubMed
    Score: 0.055
  41. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res. 1993 Feb 15; 53(4):725-7.
    View in: PubMed
    Score: 0.055
  42. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin Cancer Res. 2012 Nov 01; 18(21):6058-64.
    View in: PubMed
    Score: 0.054
  43. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report. Clin Cancer Res. 2012 Sep 15; 18(18):5081-9.
    View in: PubMed
    Score: 0.053
  44. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jan 20; 30(3):256-62.
    View in: PubMed
    Score: 0.051
  45. Current pharmacological treatment approaches to central nervous system leukaemia. Drugs. 1991 May; 41(5):702-16.
    View in: PubMed
    Score: 0.049
  46. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol. 2011 Jan 20; 29(3):324-9.
    View in: PubMed
    Score: 0.048
  47. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Feb; 56(2):226-33.
    View in: PubMed
    Score: 0.047
  48. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Sep; 55(3):440-5.
    View in: PubMed
    Score: 0.047
  49. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010 Sep 20; 28(27):4221-7.
    View in: PubMed
    Score: 0.046
  50. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010 Dec; 46(18):3287-93.
    View in: PubMed
    Score: 0.046
  51. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol. 2010 Aug 01; 28(22):3623-9.
    View in: PubMed
    Score: 0.046
  52. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol. 2008 Jun; 10(3):341-7.
    View in: PubMed
    Score: 0.040
  53. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol. 2009 Jan; 63(2):229-38.
    View in: PubMed
    Score: 0.039
  54. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. Cancer Chemother Pharmacol. 2008 Nov; 62(6):1027-37.
    View in: PubMed
    Score: 0.039
  55. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res. 2008 Feb 15; 14(4):1124-30.
    View in: PubMed
    Score: 0.039
  56. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Feb; 50(2):254-8.
    View in: PubMed
    Score: 0.039
  57. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood. 2008 Jan 15; 111(2):566-73.
    View in: PubMed
    Score: 0.038
  58. Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatr Blood Cancer. 2007 Sep; 49(3):352-7.
    View in: PubMed
    Score: 0.038
  59. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007 Apr; 9(2):145-60.
    View in: PubMed
    Score: 0.036
  60. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006 Jul; 58(1):13-23.
    View in: PubMed
    Score: 0.033
  61. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2005 Sep 01; 23(25):6172-80.
    View in: PubMed
    Score: 0.033
  62. Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Cancer Chemother Pharmacol. 2004 Jun; 53(6):482-8.
    View in: PubMed
    Score: 0.030
  63. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002 Dec; 8(12):3646-57.
    View in: PubMed
    Score: 0.027
  64. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res. 2002 Feb; 8(2):413-8.
    View in: PubMed
    Score: 0.026
  65. Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 2000 Nov-Dec; 22(6):506-9.
    View in: PubMed
    Score: 0.024
  66. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate. Clin Cancer Res. 2000 Mar; 6(3):994-7.
    View in: PubMed
    Score: 0.022
  67. Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1999 Nov-Dec; 21(6):494-500.
    View in: PubMed
    Score: 0.022
  68. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol. 1998 Jul; 16(7):2494-9.
    View in: PubMed
    Score: 0.020
  69. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol. 1998 Jan; 16(1):181-6.
    View in: PubMed
    Score: 0.019
  70. Central nervous system leukemia. Curr Opin Oncol. 1996 Jan; 8(1):13-9.
    View in: PubMed
    Score: 0.017
  71. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res. 1994 Oct 01; 54(19):5118-22.
    View in: PubMed
    Score: 0.015
  72. Pharmacologic approaches to the treatment of meningeal malignancy. Oncology (Williston Park). 1991 May; 5(5):107-16; discussion 123, 127.
    View in: PubMed
    Score: 0.012
  73. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res. 2010 Jan 15; 16(2):750-4.
    View in: PubMed
    Score: 0.011
  74. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 15; 13(6):1789-93.
    View in: PubMed
    Score: 0.009
  75. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer. 2006 Nov 01; 107(9):2291-7.
    View in: PubMed
    Score: 0.009
  76. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol. 2006 Jan 20; 24(3):507-16.
    View in: PubMed
    Score: 0.008
  77. Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. Clin Cancer Res. 2004 Aug 01; 10(15):5072-5.
    View in: PubMed
    Score: 0.008
  78. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol. 2002 Jun-Jul; 24(5):337-42.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.